Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 21 to 30 of 2440 total matches.
COVID-19 Update: Baricitinib (Olumiant) FDA-Approved for Treatment of COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
oxygenation (ECMO).1
Baricitinib was previously available for this indication
under an Emergency Use ...
The FDA has approved the oral Janus kinase (JAK) inhibitor baricitinib (Olumiant) for treatment of COVID-19 in hospitalized adults who require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Baricitinib was previously available for this indication under an Emergency Use Authorization (EUA); it remains available under an EUA for use in children 2-17 years old hospitalized with COVID-19 who require oxygen support.
Liraglutide (Victoza) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 05, 2010 (Issue 1335)
) for Type 2
Diabetes
Liraglutide (Victoza – Novo Nordisk), a glucagon-like
peptide-1 (GLP-1) receptor ...
Liraglutide (Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous
injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin (Glucophage, and others) or glimepiride (Amaryl, and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection
The Medical Letter on Drugs and Therapeutics • Oct 09, 2017 (Issue 1531)
-experienced
patients. Mavyret is also approved for treatmentnaive
patients.
HCV GENOTYPES — HCV genotype 1 ...
The FDA has approved Mavyret (Abbvie) and Vosevi
(Gilead), two new fixed-dose combinations of direct-acting
antiviral (DAA) drugs, for treatment of chronic
hepatitis C virus (HCV) infection caused by any of the
six major HCV genotypes in patients without cirrhosis
or with compensated cirrhosis. Both are approved for
use in treatment-experienced patients. Mavyret is also
approved for treatment-naive patients.
Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
that are chemically similar to endogenous hormones
such as estradiol and progesterone.1 FDA-approved
formulations ...
The FDA has approved Bijuva (TherapeuticsMD), a
fixed-dose combination of estradiol and progesterone,
for oral treatment of moderate to severe vasomotor
symptoms (hot flashes) due to menopause in women
with an intact uterus. The manufacturer is marketing
Bijuva as "the first and only FDA-approved combination
of bio-identical estradiol and bio-identical progesterone
in a single daily oral capsule".
Pembrolizumab (Keytruda) for Metastatic Melanoma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014 (Issue 1455)
pembrolizumab (Keytruda –
Merck), a human programmed death receptor-1 (PD-1)
blocking antibody, for treatment ...
The FDA has approved pembrolizumab (Keytruda –
Merck), a human programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable or
metastatic melanoma that has progressed following
treatment with ipilimumab (Yervoy) and, if the patient
is BRAF V600 mutation positive, a BRAF inhibitor. It
is the fi rst PD-1 inhibitor to be marketed in the US.
Nivolumab, another PD-1 inhibitor, is available in
Japan. Pembrolizumab was previously known as
lambrolizumab.
Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
The Medical Letter on Drugs and Therapeutics • Feb 08, 2010 (Issue 1331)
Important Copyright Message
IN THIS ISSUE (starts on next page)
Bepotastine (Bepreve) – An Ophthalmic H
1 ...
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017 (Issue 1529)
/3.6 (Novo
Nordisk), a fixed-ratio combination of insulin degludec
and the GLP-1 (glucagon-like ...
The FDA has approved Xultophy 100/3.6 (Novo
Nordisk), a fixed-ratio combination of insulin
degludec and the GLP-1 (glucagon-like peptide-1)
receptor agonist liraglutide, for once-daily treatment
of adults with type 2 diabetes inadequately controlled
on basal insulin (<50 units daily) or liraglutide (≤1.8
mg daily).
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
is no longer authorized for use in the US.1
In September, updated formulations of the mRNA
COVID-19 vaccines ...
A new 2023-2024 formulation of the adjuvanted
protein subunit COVID-19 vaccine manufactured by
Novavax that was developed to more closely target
currently circulating SARS-CoV-2 variants has been
made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12
years old. The original formulation of the Novavax
vaccine is no longer authorized for use in the US.
In September, updated formulations of the mRNA
COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were
licensed by the FDA for use in persons ≥12 years old
and...
Med Lett Drugs Ther. 2023 Nov 13;65(1689):182-3 doi:10.58347/tml.2023.1689b | Show Introduction Hide Introduction
Expanded Table: Some Vaccines for Adults (online only)
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
)
0.5 mL IM 3 doses (0, 1, and 6-12 mos) Primary series recommended
for all adults
without history ...
Lixisenatide for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide ...
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in a
fixed-ratio combination with insulin glargine (Soliqua
100/33). Lixisenatide has been available since 2013 in
many other countries as Lyxumia. It is the fifth GLP-1
receptor agonist to be approved in the US.